In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 5, 2013, Pages 1100-1108

  Roldán Alzate, Alejandro ^a,b   Frydrychowicz, Alex ^a,d   Niespodzany, Eric ^a,b   Landgraf, Ben R ^a,b   Johnson, Kevin M ^b   Wieben, Oliver ^a,b,c   Reeder, Scott B ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Madison   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

4D Flow MRI; hepatic hemodynamics; portal hypertension

Indexed keywords

ADULT; AORTA FLOW; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE; HEALTH INSURANCE; HEMODYNAMICS; HEPATIC ARTERY; HUMAN; INSTITUTIONAL REVIEW; LIVER BLOOD FLOW; LIVER DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW;

AGED, 80 AND OVER; ALGORITHMS; BLOOD FLOW VELOCITY; FEMALE; HUMANS; HYPERTENSION, PORTAL; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER CIRCULATION; LIVER CIRRHOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84876498896     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23906     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. 2009, http://www.cdc.gov/ nchs/fastats/liverdis.htm.
2. Bhathal PS, Grossman HJ,. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-337.
3. Zardi EM, Dobrina A, Uwechie V, et al. Postmeal portal flow variations in HCV-related chronic hepatitis and liver cirrhosis with and without hyperdynamic syndrome. In Vivo 2008; 22: 509-512.
4. Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E,. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011; 60: 1254-1259.
5. Burkart DJ, Johnson CD, Ehman RL, Weaver AL, Ilstrup DM,. Evaluation of portal venous hypertension with cine phase-contrast MR flow measurements: high association of hyperdynamic portal flow with variceal hemorrhage. Radiology 1993; 188: 643-648.
6. Thalheimer U, Bellis L, Puoti C, Burroughs AK,. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No. Eur J Intern Med 2011; 22: 5-7.
7. Boyer TD,. Changing clinical practice with measurements of portal pressure. Hepatology 2004; 39: 283-285.
8. Stanley AJ, Robinson I, Forrest EH, Jones AL, Hayes PC,. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM 1998; 91: 19-25.
9. Kim MY, Baik SK, Park DH, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int 2007; 27: 1103-1110.
10. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP,. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2: 523-527.
11. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 1013-1019.
12. Villanueva C, Aracil C, Colomo A, et al. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther 2009; 29: 397-408.
13. Sanyal AJ,. Hepatic venous pressure gradient: to measure or not to measure, that is the question. Hepatology 2000; 32: 1175-1176.
14. Pomier-Layrargues G, Huet P,. Measurement of hepatic venous pressure gradient: methods, interpretation, and pitfalls. In:, Sanyal A, Shah V, editors. Portal hypertension: pathobiology, evaluation, and treatment. Totowa, NJ: Humana Press; 2005.
15. Groszmann RJ, Wongcharatrawee S,. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280-282.
16. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J,. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-1624.
17. Kamath PS, Tyce GM, Miller VM, Edwards BS, Rorie DK,. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30: 401-407.
18. Feu F, Bordas JM, Luca A, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993; 18: 1082-1089.
19. Conn HO, Grace ND, Bosch J, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology 1991; 13: 902-912.
20. Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200-1205.
21. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J,. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-908.
22. Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A,. TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci 2003; 48: 542-550.
23. Ganger DR, Klapman JB, McDonald V, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis-review of indications and problems. Am J Gastroenterol 1999; 94: 603-608.
24. de Vries PJ, van Hattum J, Hoekstra JB, de Hooge P,. Duplex Doppler measurements of portal venous flow in normal subjects. Inter- and intra-observer variability. J Hepatol 1991; 13: 358-363.
25. Thabut D, Moreau R, Lebrec D,. Noninvasive Assessment of Portal Hypertension in Patients With Cirrhosis. Hepatology 2011; 53: 683-694.
26. Vizzutti F, Arena U, Rega L, et al. Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. Liver Int 2007; 27: 1379-1388.
27. Paulson EK, Kliewer MA, Frederick MG, Keogan MT, DeLong DM, Nelson RC,. Doppler US measurement of portal venous flow: variability in healthy fasting volunteers. Radiology 1997; 202: 721-724.
28. Gouya H, Mallet V, Scatton O, et al. Magnetic resonance imaging (MRI) flow, a new non-invasive method for the evaluation of systemic, splanchnic, and azygos blood flows in patients with portal hypertension. Hepatology 2008; 48: 1049A-1049A.
29. Wu MT, Pan HB, Chen C, et al. Azygos blood flow in cirrhosis: measurement with MR imaging and correlation with variceal hemorrhage. Radiology 1996; 198: 457-462.
30. Stankovic Z, Frydrychowicz A, Csatari Z, et al. MR-based visualization and quantification of three-dimensional flow characteristics in the portal venous system. J Magn Reson Imaging 2010; 32: 466-475.
31. Frydrychowicz A, Landgraf BR, Niespodzany E, et al. Four-dimensional velocity mapping of the hepatic and splanchnic vasculature with radial sampling at 3 Tesla: a feasibility study in portal hypertension. J Magn Reson Imaging 2011; 34: 577-584.
32. Gu T, Korosec FR, Block WF, et al. PC VIPR: a high-speed 3D phase-contrast method for flow quantification and high-resolution angiography. AJNR Am J Neuroradiol 2005; 26: 743-749.
33. Johnson KM, Markl M,. Improved SNR in phase contrast velocimetry with five-point balanced flow encoding. Magn Reson Med 2010; 63: 349-355.
34. Johnson KM, Francois C, Lum D, et al. Rapid comprehensive evaluation of luminography and hemodynamic function with 3D radially undersampled phase contrast imaging MRI. Conf Proc IEEE Eng Med Biol Soc 2009; 1: 4057-4060.
35. Liu J, Redmond MJ, Brodsky EK, et al. Generation and visualization of four-dimensional MR angiography data using an undersampled 3-D projection trajectory. IEEE Trans Med Imaging 2006; 25: 148-157.
36. Bernstein MA, Xiaohong JZ, Zhou J, et al. Concomitant gradient terms in phase contrast MR: Analysis and correction. Magn Reson Med 1998; 39: 300-308.
37. Walker PG, Cranney GB, Scheidegger MB, Waseleski G, Pohost GM, Yoganathan AP,. Semiautomated method for noise reduction and background phase error correction in MR phase velocity data. J Magn Reson Imaging 1993; 3: 521-530.
38. Johnson KM, Lum DP, Turski PA, Block WF, Mistretta CA, Wieben O,. Improved 3D phase contrast MRI with off-resonance corrected dual echo VIPR. Magn Reson Med 2008; 60: 1329-1336.
39. Stalder AF, Russe MF, Frydrychowicz A, Bock J, Hennig J, Markl M,. Quantitative 2D and 3D phase contrast MRI: optimized analysis of blood flow and vessel wall parameters. Magn Reson Med 2008; 60: 1218-1231.
40. Chow PK, Yu WK, Soo KC, Chan ST,. The measurement of liver blood flow: a review of experimental and clinical methods. J Surg Res 2003; 112: 1-11.
41. Ludwig D, Schwarting K, Korbel CM, Bruning A, Schiefer B, Stange EF,. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 1998; 28: 631-638.
42. Siringo S, Piscaglia F, Zironi G, et al. Influence of esophageal varices and spontaneous portal-systemic shunts on postprandial splanchnic hemodynamics. Am J Gastroenterol 2001; 96: 550-556.